Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hauschild

Showing results (1101-1110 of 1,351) with videos related to

Pageof 136
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
European Journal of Dermatology : EJD|January 31, 2019
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Karen Bartley, Thomas Karagiannis, et al.
International Journal of Molecular Sciences|December 11, 2022
Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate CancerGunhild von Amsberg, Mirjam Zilles, Wael Mansour, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Plos One|September 15, 2010
Identifying Fishes through DNA Barcodes and MicroarraysMarc Kochzius, Christian Seidel, Aglaia Antoniou, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Scientific Reports|March 1, 2017
Rapid adaptation to microgravity in mammalian macrophage cellsCora S Thiel, Diane de Zélicourt, Svantje Tauber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Cancers|November 2, 2019
Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-NaphthoquinonesSergey A Dyshlovoy, Dmitry N Pelageev, Jessica Hauschild, et al.
The Oncologist|March 5, 2013
Analysis of dermatologic events in vemurafenib-treated patients with melanomaMario E Lacouture, Madeleine Duvic, Axel Hauschild, et al.
Pageof 136

Showing results (1101-1110 of 1,351) with videos related to

Sort By:
Pageof 136
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
European Journal of Dermatology : EJD|January 31, 2019
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Karen Bartley, Thomas Karagiannis, et al.
International Journal of Molecular Sciences|December 11, 2022
Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate CancerGunhild von Amsberg, Mirjam Zilles, Wael Mansour, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Plos One|September 15, 2010
Identifying Fishes through DNA Barcodes and MicroarraysMarc Kochzius, Christian Seidel, Aglaia Antoniou, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Scientific Reports|March 1, 2017
Rapid adaptation to microgravity in mammalian macrophage cellsCora S Thiel, Diane de Zélicourt, Svantje Tauber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Cancers|November 2, 2019
Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-NaphthoquinonesSergey A Dyshlovoy, Dmitry N Pelageev, Jessica Hauschild, et al.
The Oncologist|March 5, 2013
Analysis of dermatologic events in vemurafenib-treated patients with melanomaMario E Lacouture, Madeleine Duvic, Axel Hauschild, et al.
Pageof 136